The study of MicRNA 107 and BACE1 mRNA gene expression in peripheral blood and cerebrospinal fluid of Alzheimer's disease

tao wang,huafang li,ning su,yuanyuan liu,yan cheng,shuhui dong,cece yang,shifu xiao

DOI: https://doi.org/10.1016/j.jalz.2013.05.460

2013-01-01

Alzheimer s & Dementia

Abstract:To investigate the relationship and diagnosis capability of MicRNA 107 and BACE1 mRNA gene expression in aMCI from normal control. We recruited 97 AD patients, 116 aMCI subjects and 81 normal controls in the research. The peripheral blood sample was collected for all of the subjects. 45 AD patients were collected CSF sample. The Real-Time PCR was the main method in the research. There were no significant difference of age, gender and education level in three groups. The levels of MicRNA107 expression in AD, aMCI and NC were 1.31 ± 1.12, 1.02 ± 0.51 and 3.98 ± 1.88 respectively. The levels of Bace1mRNA expression in AD, aMCI and NC were 0.64 ± 0.24, 0.74 ± 0.19 and 0.43 ± 0.14 respectively. There was statistical significant correlations between plasma MicRNA 107 and BACE1 mRNA gene expression in AD, aMCI and NC (r value -0.316, -0.615 and -0.367, P value 0.002, <0.001 and 0.001 respectively). The function of plasma MicRNA 107 and BACE1 mRNA gene expression discrimination aMCI and NC was D=0.597xMicRNA107 expression - 2.594xBACE1 mRNA expression +0.253. 87.8% of original grouped cases correctly classified. The group of aMCI has the lowest level of MicRNA107 expression and the highest level of Bace1mRNA the expression in plasma in three groups. The level of MicRNA107 expression in plasma has a high capability to discriminate the aMCI from normal control. The plasma MicRNA 107 and BACE1 mRNA gene expression could represent the expression in CSF.